Human Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASC42, a Novel Farnesoid X Receptor Agonist

por He, Handan, Wu, Jinzi J.
Publicado 2023

Long-term positive severe acute respiratory syndrome coronavirus 2 ribonucleic acid and therapeutic effect of antivirals in patients with coronavirus disease: Case reports

por Wei, Bo, Hang, Xiaofeng, Xie, Ying, Zhang, Yuanjing, Wang, Jianrong, Cao, Xinghao, Wu, Jinzi J., Wang, Junxue
Publicado 2020

First clinical study using HCV protease inhibitor danoprevir to treat COVID-19 patients

por Chen, Hongyi, Zhang, Zhicheng, Wang, Li, Huang, Zhihua, Gong, Fanghua, Li, Xiaodong, Chen, Yahong, Wu, Jinzi J.
Publicado 2020

Efficacy and Safety of 12-week Interferon-based Danoprevir Regimen in Patients with Genotype 1 Chronic Hepatitis C

por Wei, Lai, Shang, Jia, Ma, Yuanji, Xu, Xiaoyuan, Huang, Yan, Guan, Yujuan, Duan, Zhongping, Zhang, Wenhong, Gao, Zhiliang, Zhang, Mingxiang, Li, Jun, Jia, Jidong, Yang, Yongfeng, Wen, Xiaofeng, Wang, Maorong, Jia, Zhansheng, Ning, Bo, Chen, Yongping, Qi, Yue, Du, Jie, Jiang, Jianning, Tong, Lixin, Xie, Yao, Wu, Jinzi J.
Publicado 2019

Efficacy and Safety of All-oral, 12-week Ravidasvir Plus Ritonavir-boosted Danoprevir and Ribavirin in Treatment-naïve Noncirrhotic HCV Genotype 1 Patients: Results from a Phase 2/...

por Xu, Xiaoyuan, Feng, Bo, Guan, Yujuan, Zheng, Sujun, Sheng, Jifang, Yang, Xingxiang, Ma, Yuanji, Huang, Yan, Kang, Yi, Wen, Xiaofeng, Li, Jun, Tan, Youwen, He, Qing, Xie, Qing, Wang, Maorong, An, Ping, Gong, Guozhong, Liu, Huimin, Ning, Qin, Hua, Rui, Ning, Bo, Xie, Wen, Zhang, Jiming, Huang, Wenxiang, Yang, Yongfeng, Lin, Minghua, Zhao, Yingren, Yu, Yanhong, Jia, Jidong, Yang, Dongliang, Chen, Liang, Ye, Yinong, Nan, Yuemin, Gong, Zuojiong, Zhang, Quan, Hu, Peng, Wang, Fusheng, Li, Yongguo, Li, Dongliang, Jia, Zhansheng, Hou, Jinlin, Chen, Chengwei, Wu, Jinzi J., Wei, Lai
Publicado 2019